MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.
- MINDCURE recognizes the importance of sustainability, excellence, and reliability regarding the materials it uses in product development and research.
- By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine, while ensuring consistent dosing and reliable results.
- Ibogaine has unique and broad actions in the brain, affecting multiple receptors and neurotransmitter systems.
- Ibogaine offers incredible therapeutic potential, especially in the context of neuroregeneration," said Dr. Ryan Hartwell, Chief Science Officer, MINDCURE.